The historical rank and industry rank for Avacta Group's Days Inventory or its related term are showing as below:
During the past 13 years, Avacta Group's highest Days Inventory was 51903.00. The lowest was 70.51. And the median was 104.43.
LSE:AVCT's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 183.875 * Ranked among companies with meaningful Days Inventory only.
Avacta Group's Days Inventory
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Avacta Group's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.00.
Avacta Group (LSE:AVCT) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Avacta Group's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Avacta Group's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Avacta Group Days Inventory Related Terms
Avacta Group Days Inventory Historical Data
* Premium members only.
The historical data trend for Avacta Group's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:AVCT vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Avacta Group's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avacta Group Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avacta Group's Days Inventory distribution charts can be found below:
* The bar in red indicates where Avacta Group's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avacta Group (LSE:AVCT) has a Days Inventory of 0.00 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Avacta Group and its competitors. Over the past decade, Avacta Group's Days Inventory has ranged from 70.51 to 51,903.00. According to the industry distribution chart, Avacta Group ranks #999999 out of 638 companies in the Biotechnology industry.
Is Avacta Group's Days Inventory too high?
Avacta Group's current Days Inventory is 0.00. Over the past 10 years, this metric has ranged from a low of 70.51 to a high of 51,903.00. Based on the distribution chart, Avacta Group ranks #999999 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avacta Group has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #999999 out of 638 companies for Days Inventory. This places Avacta Group in the lower half of its industry. The industry median Days Inventory is 183.88. Historically, Avacta Group's own Days Inventory has ranged from 70.51 to 51,903.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Avacta Group and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avacta Group's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (LSE:AVCT) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.49, compared to a current price of £0.74 — trading 50% above its estimated fair value. The current Days Inventory is 0.00. Avacta Group's overall GF Score™ is 28/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Avacta Group (LSE:AVCT), the current Days Inventory is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avacta Group (LSE:AVCT) Overvalued in 2026?
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of £0.74 is trading 50% above its estimated GF Value™ of £0.49.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for LSE:AVCT:
Days Inventory: 0.00
GF Value™: £0.49 vs. price of £0.74 (50% above fair value)
No single metric tells the full story. See the LSE:AVCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
28GF Score
Get the complete analysis for LSE:AVCT
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:AVCT has been successfully added to your 
